Proton Pump Inhibitor (PPI) Inappropriate Use and Economic Burden in Chinese Population
ECHO
1 other identifier
observational
90,895
1 country
1
Brief Summary
This is a descriptive retrospective database analysis study in using database. All patients with a physician PPI prescription will be selected to estimate the PPI inappropriate use.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2017
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 13, 2017
CompletedFirst Posted
Study publicly available on registry
April 18, 2017
CompletedStudy Start
First participant enrolled
April 28, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 10, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
July 10, 2017
CompletedJuly 12, 2018
June 1, 2018
2 months
April 13, 2017
July 11, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall proportion of patient inappropriate use of PPI
Overall number of patient times/courses with PPI inappropriate use (including non-indication use, over maximum daily dose and over maximum duration) divided by the total number of patient-times/courses with PPI use for both outpatients and inpatients.
2015.01-2015.12
Eligibility Criteria
Patients who were prescribed PPIs during Jan. 2015 to Dec. 2015 will be identified and then all their inpatient and outpatient information will be extracted.
You may qualify if:
- All patients in 2015 China Health Insurance Research Association (CHIRA) database.
- Patients had PPI prescription during Jan. 2015 to Dec. 2015 will be selected to estimate the PPI inappropriate use.
You may not qualify if:
- Patients without data of treatment information.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (1)
Research Site
Beijing, 100013, China
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 13, 2017
First Posted
April 18, 2017
Study Start
April 28, 2017
Primary Completion
July 10, 2017
Study Completion
July 10, 2017
Last Updated
July 12, 2018
Record last verified: 2018-06